The Evidence Behind TPE
Last updated: November 9, 2026
Part of Blood Rehabilitation:RemoveRestoreSupport
- 8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258
- (623) 294-5577
- Monday to Friday, 9 a.m. to 5 p.m.
What the evidence shows: Therapeutic Plasma Exchange and Biological Age
“Biological age” is an estimate, based on blood and molecular markers, of how your body is aging compared with your calendar age. It is a measurement, not a diagnosis, and different tests can give different answers.
What the studies show. In a 2025 randomized, placebo-controlled trial of 42 healthy adults over 50, people who had plasma exchange scored lower on several biological-age measures than people who had a placebo. Smaller human studies point the same way. In the studies that found a benefit, the largest changes came after the first few sessions. One report says people who started with less healthy markers changed the most. In animal studies (specifically in aged mice), exchanging old plasma for a saline-and-albumin solution, with no young blood, improved measures of muscle repair, liver scarring, and new nerve cell growth in the brain. That said, animal results often do not carry over to people.
What we do not know. These human studies are small and early. They measured markers, not longer life or fewer illnesses, and no study has tested either one. Results have not yet proven to be consistent.
Where this leaves us. Based on the limited body of research on this topic, using plasma exchange to affect biological age is still a research question. It may suit adults who want to track their own aging markers and understand that the evidence is preliminary. We measure your labs before and after, so you see your own change, whatever it turns out to be.
- Borsky P, Holmannová D, Párová H, et al. Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial). Scientific Reports. 2025;15. doi:10.1038/s41598-025-05396-0
- Fuentealba M, Kiprov D, Schneider K, et al. Multi‐Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single‐Blinded Randomized Placebo‐Controlled Therapeutic Plasma Exchange. Aging Cell. 2025;24. doi:10.1111/acel.70103
- Gulej R, Patai R, Ungvari A, et al. Plasma-based strategies for systemic rejuvenation: critical perspectives on clinical translation. GeroScience. 2026;48:4571 - 4584. doi:10.1007/s11357-026-02136-8
- Kim D, Kiprov D, Luellen C, et al. Old plasma dilution reduces human biological age: a clinical study. GeroScience. 2022;44:2701 - 2720. doi:10.1007/s11357-022-00645-w
- Liu S, Wang S, Dong Y, Yang S, Yao C. Research progress on blood therapy for anti-aging. Journal of Advanced Research. 2025;82:981 - 998. doi:10.1016/j.jare.2025.07.039
- Rony R, Shokrani A, Malhi N, et al. Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease. Biomolecules. 2025;15. doi:10.3390/biom15071000
What the evidence shows: Autoimmune and chronic inflammatory conditions
Autoimmune conditions are where TPE has its longest track record. In many of them, harmful antibodies circulate in the plasma, and TPE removes plasma along with those antibodies, immune complexes, and some inflammatory proteins.
What the guidelines say. The American Society for Apheresis (ASFA) rates each use of apheresis from first-line therapy to “best role not established.” It accepts TPE as first-line therapy for Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and acute worsening of myasthenia gravis.¹ It accepts TPE as second-line therapy for conditions such as multiple sclerosis relapses, attacks of neuromyelitis optica spectrum disorder, severe cryoglobulinemia, and severe lupus.¹ For a few uses, such as paraneoplastic neurological syndromes, the guidelines say the best role has not been established.¹ A 2023 review also reports improvements in clinical and laboratory measures in several of these conditions.² In them, TPE can calm a flare while other medicines take effect.
What it does not do. TPE removes antibodies already in the blood. It does not stop the cells that make them, so antibodies can return after treatment. Long-term control usually needs medicines that suppress the immune system.² For general “inflammation” without a specific diagnosis, the evidence is limited.
Safety. Common reactions include low blood pressure, low calcium, and fainting-type reactions.²
How we work. If you have a diagnosed autoimmune condition, plasma exchange should be decided and overseen by your own specialist, such as a neurologist, rheumatologist, or nephrologist. We do not replace that care. We can measure your labs before and after, and share the results with your specialist.
See TPE for Autoimmune & Chronic Inflammatory Conditions.
- Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38(2):77-278. doi:10.1002/jca.22043
- Altobelli C, Anastasio P, Cerrone A, et al. Therapeutic plasmapheresis: a revision of literature. Kidney Blood Press Res. 2023;48(1):66-78. doi:10.1159/000528556
What the evidence shows: Cardiovascular Health
Established. ApoB is a recognized marker of cardiovascular risk. Many lipid experts now use ApoB as a more precise guide than LDL cholesterol.¹
What the guidelines say. The American Society for Apheresis (ASFA) accepts plasma exchange as a second-line therapy in familial hypercholesterolemia, an inherited condition that causes very high cholesterol. It also accepts plasma exchange as first-line for symptomatic hyperviscosity, where very high protein levels thicken the blood.²
What plasma exchange is believed to do. Plasma exchange removes all of the plasma, including cholesterol-carrying particles and inflammatory proteins, and replaces it, usually with albumin. A series is expected to lower these for a time. In one study, five exchanges lowered apolipoprotein C-III and the ApoB-to-ApoA-1 ratio, while triglycerides and VLDL changed little.³ In aged diabetic mice, exchanging about half the plasma improved recovery from blocked blood flow.⁴ Animal results often do not carry over to people. Levels rise again as the body makes more, which is why sessions are repeated.
What has not been shown. To date we are not aware of trials showing that plasma exchange lowers the risk of heart attack or stroke in people with elevated risk factors, and routine preventive use is yet unproven. This Program does not claim it works that way. It measures your numbers before and after, so you and your clinicians can see what changed.
How we work. This Program supports your current care. It does not replace statins, ezetimibe, PCSK9 inhibitors, or your cardiologist or primary care provider.
See TPE for Cardiovascular Health.
- Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013
- Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38(2):77-278. doi:10.1002/jca.22043
- Pitkänen HH, Haapio M, Saarela M, et al. Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation. Transfus Apher Sci. 2024;63(3):103918. doi:10.1016/j.transci.2024.103918
- Rony RMIK, Shokrani A, Malhi NK, et al. Therapeutic plasma exchange: current and emerging applications to mitigate cellular signaling in disease. Biomolecules. 2025;15(7):1000. doi:10.3390/biom15071000
- Altobelli C, Anastasio P, Cerrone A, et al. Therapeutic plasmapheresis: a revision of literature. Kidney Blood Press Res. 2023;48(1):66-78. doi:10.1159/000528556
What the evidence shows: Brain health and cognitive function
The main trial. AMBAR (Alzheimer Management by Albumin Replacement) is the largest randomized trial of plasma exchange in Alzheimer’s disease. It enrolled 347 people with mild to moderate Alzheimer’s in Spain and the US. Participants were randomly assigned to one of three plasma exchange regimens with albumin, or to a sham (placebo) procedure. Treatment lasted about 14 months: six weekly exchanges, followed by 12 smaller monthly ones. The results were published in 2020.¹
What it found. Across everyone treated, daily functioning (such as dressing and managing household tasks) declined about half as much as with the sham procedure, a difference large enough to be statistically meaningful. Memory and thinking also declined less, but that difference narrowly missed statistical significance. In people with moderate Alzheimer’s, both measures declined by less than half as much as with sham. The researchers concluded that the approach may slow decline but that more studies are needed.¹
Further analyses. In additional (secondary) analyses of the same trial, people who received plasma exchange declined less on a clinician-rated dementia scale, with about 70% less decline. They also had better quality of life and verbal memory.¹,² Secondary results are less certain than the main results, because the trial was not designed around them.
Outside the trial. A real-world study in Argentina followed 32 people who received plasma exchange for about a year. On a standard memory-and-thinking screening test, their scores declined about 45% less than those of comparison patients taken from past records.³ This kind of comparison is weaker than a randomized trial, because the groups may differ in ways that have nothing to do with treatment.
The idea behind it. This is a working hypothesis. Albumin in the blood binds most of the amyloid-beta protein, so replacing plasma with fresh albumin may shift how amyloid-beta moves between the blood and the brain.¹ Plasma exchange may also remove inflammatory proteins and supply albumin that is less oxidized.⁴ In a mouse model of Alzheimer’s disease, plasma exchange lowered amyloid plaques in the brain.⁵ Animal results often do not carry over to people.
What has not been shown. AMBAR enrolled people who already had Alzheimer’s. This trial does not show that plasma exchange prevents dementia or sharpens thinking in healthy people, and we are not aware of trials that have tested this. Brain health remains an investigational area for plasma exchange. If you or a family member has a diagnosis, please involve your neurologist before considering it.
See TPE for Brain Health & Cognitive Function and our AMBAR trial summary.
- Boada M, López OL, Olazarán J, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: primary results of the AMBAR study. Alzheimers Dement. 2020;16(10):1412-1425. doi:10.1002/alz.12137
- Boada M, López OL, Olazarán J, et al. Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer’s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. Alzheimers Dement. 2022;18(7):1314-1324. doi:10.1002/alz.12477
- Taragano F, Seinhart D, Epstein P, et al. A real-world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer’s disease. J Alzheimers Dis. 2025;108:129-141. doi:10.1177/13872877251375430
- Imbimbo BP, Ippati S, Ceravolo F, Watling M. Perspective: is therapeutic plasma exchange a viable option for treating Alzheimer’s disease? Alzheimers Dement (N Y). 2020;6(1):e12004. doi:10.1002/trc2.12004
- Ramirez S, Koerich S, Astudillo N, et al. Plasma exchange reduces Aβ levels in plasma and decreases amyloid plaques in the brain in a mouse model of Alzheimer’s disease. Int J Mol Sci. 2023;24(23):17087. doi:10.3390/ijms242317087
- Boada M, Kiprov D, Anaya F, et al. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer’s disease in the AMBAR study. J Clin Apher. 2023;38(1):45-54. doi:10.1002/jca.22026
Environmental Exposure: Mold, Microplastics & Environmental Toxins
From TPE for Environmental Exposure.
- Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022;163:107199.
- Centers for Disease Control and Prevention. Mold Prevention Strategies and Possible Health Effects in the Aftermath of Hurricanes and Major Floods. MMWR Recomm Rep. 2006;55(RR-8):1-27.
Women's Health
From TPE for Women's Health.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. Reaffirmed 2024.
Additional reading
Borsky et al. — Human clinical trial of plasmapheresis effects on biomarkers of aging (2025), PMC12218284. Researchers studied repeated plasma donation in healthy adults aged 40–60, without albumin or young-plasma replacement. Thirty-four participants completed the 18-week study. Some blood measurements changed, but no significant epigenetic rejuvenation was found; several aging-clock measures increased. This protocol differs from albumin-replacement TPE and does not establish a lifespan benefit.
Last updated
Last updated: November 9, 2026. New research is added here as it's published.

Questions worth asking any clinic, including ours.
Before you decide, ask us these. We’ll answer them plainly.
- What is the evidence for this use of TPE, and how strong is it?
- What will my Focused panel measure, what would an Expanded panel add, and how will we know what changed?
- What are the risks, and who should not have this procedure?
- What will it cost in total? (The Focused panel is included; the Expanded panel is an additional fee.)
- How will my own physician or clinician be kept informed?
Call us or send a request online, and our clinical team will answer your questions and set up a consultation.
Visit or call the clinic
Blood Rehabilitation Centers, Scottsdale, Arizona. Call us or send a request online, and our clinical team will answer your questions and set up a consultation.
Call (623) 294-5577- 8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258
- Monday to Friday, 9 a.m. to 5 p.m.
What would you like to understand?
Browse all pages
- Home
- Blood Rehabilitation
- How We Prove It
- Programs
- The Vitality Cascade
- Membership
- TPE / Plasmapheresis
- TPE Fees & Packages
- How ClearCycle™ TPE Works
- The Evidence Behind TPE
- TPE Patient Experience
- eBoo
- EBO2 Fees & Packages
- How EBO2 Works
- EBO2 Patient Experience
- Safety & Standards
- Dr. David George
- Team
- For referring clinicians
- Contact Us in Scottsdale
- Frequently Asked Questions
- Privacy
- Terms & Conditions
- Cookie Policy
- Accessibility
- TPE for Biological Age
- TPE for Autoimmune & Chronic Inflammatory Conditions
- TPE for Cardiovascular Health
- TPE for Brain Health & Cognitive Function
- TPE for Environmental Exposure: Mold, Microplastics & Environmental Toxins
- TPE for Women’s Health
- Cardiovascular Health Program
- Biological Age
- Brain Health
- Autoimmune
- Environmental Exposure Program
- Women’s Health
- Performance Blood Health
- AMBAR trial summary